Neurocrine Biosciences (NBIX) said it has obtained exclusive rights for all indications to develop and commercialize osavampator for patients with inadequate response to treatment of major depressive disorder following an amended agreement with Takeda Pharmaceuticals.
The rights are for all territories worldwide, except Japan, where Takeda will reacquire exclusive rights, according to a statement late Monday. Each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。